July 2011 – Study published in Gastroenterology finds that patients who took sitagliptin (one of the main active ingredients in Janumet) were twice as likely to get pancreatic cancer compared to people who took other types of diabetes drugs.
July 2011 – Study published in Gastroenterology finds that patients who took sitagliptin (one of the main active ingredients in Janumet) were twice as likely to get pancreatic cancer compared to people who took other types of diabetes drugs.